Advertisement

Melatonin and Immune Function: Clinical Significance

  • Mahaneem MohamedEmail author
  • Venkataramanujam Srinivasan
  • Georges Maestroni
  • Ruth E. Rosenstein
  • Sukru Oter
Chapter

Abstract

The immune system of the body plays an important role in fighting against cancer and infectious diseases. The decreased immune function has been primarily attributed to the increased incidence of neoplastic and infectious diseases in the elderly. Alteration in circadian rhythmicity of various subsets of lymphocyte population in cancer patients suggests impaired integration of nervous, endocrine, and immune responses in neoplastic disease. The photoperiodic regulation of immune function with enhancement during short photoperiods and inhibition during long photoperiods is supported by the seasonal outbreak of some infectious diseases. The pineal biomolecule melatonin could be a very useful resource for inhibiting neoplastic growth as its immunomodulatory role may stimulate several immune mechanisms. Melatonin stimulates natural killer cells which are known to attack and destroy cancerous cells. It also influences T-helper 1 cells, B lymphocytes, and release of cytokines from immunoregulatory cells. The immunomodulatory role for melatonin and its application in the control of infectious and neoplastic diseases is supported by the synthesis of melatonin by lymphocytes and thymus.

Keywords

Melatonin Immune mechanism Lymphocytes Innate immunity Adaptive immunity Cancer Infectious diseases 

Abbreviations

AFMK

N1-acetyl-N2-formyl-5-methoxykynuramine

CCL

Chemokine ligand

COX2

Cyclooxygenase-2

CSF

Cerebrospinal fluid

DPSCs

Dental pulp stem cells

GH

Growth hormone

GSH

Glutathione

hESCs

Human embryonic stem cells

HIV

Human immunodeficiency virus

HLA

Human leukocyte antigen

hMSCs

Human mesenchymal stem cells

IFN

Interferon

Ig

Immunoglobulin

IL

Interleukin

M-CSF

Macrophage colony-stimulating factor

NFκB

Nuclear factor kappa B

NK

Natural killer

NR1F1

Nuclear receptor subfamily 1 group F, member 1

O2−•

Superoxide anion (radical)

OSCSCs

Oral squamous carcinoma stem cells

RAR

Retinoic acid receptor

ROR

RAR-related orphan receptor-α

SCF

Stem cell factor

TCR

T-cell receptor

TGF-β

Transforming (or tumor) growth factor

TNF-α

Tumor necrosis factor-α

TSH

Thyroid-stimulating hormone

References

  1. 1.
    Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Lofgren S, et al. An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and non octogenarian humans. J Gerontol A Biol Sci Med Sci. 2005;60:556–65.PubMedGoogle Scholar
  2. 2.
    Pawelec G, Ouyang Q, Colonna-Romono G, Candore G, Lio D, Caruso C. Is human immunosenescence clinically relevant? Looking for immunological risk phenotypes. Trends Immunol. 2002;23:330–2.PubMedGoogle Scholar
  3. 3.
    Tarazona R, Solana R, Ouyang Q, Pawelec G. Basic biology and clinical impact of immunosenescence. Exp Gerontol. 2002;37:183–9.PubMedGoogle Scholar
  4. 4.
    Ligthart GJ, Corberand JX, Fournier C, Galanaud P, Hiljmans W, Kennes B, et al. Admission criteria for immunogeronto-logical studies in man: the SENIEUR protocol. Mech Ageing Dev. 1984;28:47–55.PubMedGoogle Scholar
  5. 5.
    Fietta A, Merlini C, Dos Santos C, Rovida S, Grassi C. Influence of aging on some specific and nonspecific mechanisms of the host defense system in 146 healthy subjects. Gerontology. 1994;40:237–45.PubMedGoogle Scholar
  6. 6.
    Ahluwalia N. Aging, nutrition and immune function. J Nutr. 2004;8(1):2–6.Google Scholar
  7. 7.
    Arit W, Hewison M. Hormones and immune function: implications of aging. Aging Cell. 2004;3:209–16.Google Scholar
  8. 8.
    Srinivasan V, Maestroni GJM, Cardinali DP, Esquifino AI, Pandi-Perumal SR, Miller SC. Melatonin, immune function and aging. Immun Aging. 2005;2:17. http://www.immunityageing.com/content/2/1/17. Accessed on 24 Apr 2012.Google Scholar
  9. 9.
    Nelson RJ. Seasonal immune function and sickness responses. Trends Immunol. 2004;25:187–92.PubMedGoogle Scholar
  10. 10.
    Reichlin S. Neuroendocrine-immune interactions. N Engl J Med. 1993;329:1246–53.PubMedGoogle Scholar
  11. 11.
    Srinivasan V. Psychoneuroimmunology. Indian J Clin Pract. 1995;5(11):39–41.Google Scholar
  12. 12.
    Ginaldi L, Loreto MF, Corsi MP, Modesti M, Martinis M. Immuno-senescence and infectious diseases. Microbes Infect. 2001;3:851–7.PubMedGoogle Scholar
  13. 13.
    Colonna-Romano G, Bulati M, Aquino A, Scialabba G, Candore G, Lio D, et al. B cells in the aged: CD27, CD5, and CD 40 expression. Mech Ageing Dev. 2003;124:389–93.PubMedGoogle Scholar
  14. 14.
    Weksler ME, Szabo P. The effect of age on the B-cell response. J Clin Immunol. 2000;20:240–9.PubMedGoogle Scholar
  15. 15.
    Tian YM, Zhang GY, Dai YR. Melatonin rejuvenates thymus and redresses peripheral immune functions in aged mice. Immunol Lett. 2003;88:101–4.PubMedGoogle Scholar
  16. 16.
    Mazzoccoli G, DeCata A, Carughi S, Greco A, Inglese M, Perfetto F, et al. A possible mechanism for altered immune response in the elderly. In Vivo. 2010;24(4):471–87.PubMedGoogle Scholar
  17. 17.
    Mazzoccoli G, Inglese M, De Cata A, Carughi S, Dagostino MP, Marzulli N, et al. Neuroendocrine-immune interactions in healthy aging. Geriatr Gerontol. 2011;11:98–106.Google Scholar
  18. 18.
    Mazzoccoli G, Sothern RB, De Cata A, Giuliani F, Fontana A, Copetti M, et al. A timetable of 24-hour patterns for human lymphocyte subpopulations. J Biol Regul Homeost Agents. 2011;25(3):387–95.PubMedGoogle Scholar
  19. 19.
    Mazzoccoli G, Vendemiale G, De Cata A, Tarquini R. Change of γδ TCR-expressing T cells in healthy aging. Int J Immunopathol Pharmacol. 2011;24:201–9.PubMedGoogle Scholar
  20. 20.
    Bensussan A, Lagabrielle JF, Degos L. TcRγδ bearing lymphocyte clones with lymphokine activated killer activity against autologous leukemic cells. Blood. 1989;15:135–9.Google Scholar
  21. 21.
    Mazzoccoli G, Vendemiale M, La Viola A, De Cata A, Carughi A, Greco A, et al. Circadian variations of cortisol, melatonin, and lymphocyte subpopulations in geriatric age. Int J Immunopathol Pharmacol. 2010;23(1):289–96.PubMedGoogle Scholar
  22. 22.
    Hakim FT, Flomerfelt FA, Boyiadzis M, Gress RE. Aging, immunity and cancer. Curr Opin Immunol. 2004;16:151–6.PubMedGoogle Scholar
  23. 23.
    Borrego F, Alonso MC, Galiani MD, Carracedo J, Ramirez R, Ostos B, et al. NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol. 1999;34:253–65.PubMedGoogle Scholar
  24. 24.
    Ginaldi L, De Martinis M, D’Ostillo A, Marini L, Loreto MF, Quaglino D. The immune system in the elderly: III. Innate immunity. Immunol Res. 1999;20:117–26.PubMedGoogle Scholar
  25. 25.
    Mariani E, Meneghetti A, Neri S, Ravaglia G, Forti P, Cattini L, et al. Chemokine production by natural killer cells from nonagenarians. Eur J Immunol. 2002;32:1524–9.PubMedGoogle Scholar
  26. 26.
    Krishnaraj R. Senescence and cytokine modulate the NK cell expression. Mech Ageing Dev. 1997;96:89–101.PubMedGoogle Scholar
  27. 27.
    Fulop Jr T, Foris G, Worum I, Paragh G, Leovey A. Age related variations of some polymorphonuclear leukocytes functions. Mech Ageing Dev. 1985;29:1–8.PubMedGoogle Scholar
  28. 28.
    Miyagi C, Watanabe H, Toma H, Akisaka M, Tomiyama K, Sato Y, et al. Functional alteration of granulocytes, NK cells, and natural killer cells in centenarians. Hum Immunol. 2000;61:908–16.Google Scholar
  29. 29.
    Lipschitz DA, Udupa KB, Boxer LA. The role of calcium in the age related decline of neutrophil function. Blood. 1988;71:659–65.PubMedGoogle Scholar
  30. 30.
    Lord JM, Butcher S, Killampali V, Lascelles D, Salmon M. Neutrophil ageing and immunosenescence. Mech Ageing Dev. 2001;122:1521–35.PubMedGoogle Scholar
  31. 31.
    Castle SC. Clinical relevance of age related immune dysfunction. Clin Infect Dis. 2000;31:578–85.PubMedGoogle Scholar
  32. 32.
    Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflam-aging. An evolutionary perspective on immune-senescence. Ann N Y Acad Sci. 2000;908:244–54.PubMedGoogle Scholar
  33. 33.
    Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc. 1993;41:176–81.PubMedGoogle Scholar
  34. 34.
    Mysliwska J, Bryl E, Foerster J, Mysliwski A. Increase of interleukin-6 and decrease of interleukin-2 production during the ageing process are influenced by the health status. Mech Ageing Dev. 1998;100:313–28.PubMedGoogle Scholar
  35. 35.
    Straub RH, Miller LE, Scholmerich J, Zietz B. Cytokines and hormones as possible links between endocrinosenescence and immunosenescence. J Neuroimmunol. 2000;109:10–5.PubMedGoogle Scholar
  36. 36.
    Forsey RJ, Thompson JM, Ernerudh J, Hurst JL, Strindhall J, Johansson B, et al. Plasma cytokine profiles in elderly humans. Mech Ageing Dev. 2003;124:487–93.PubMedGoogle Scholar
  37. 37.
    Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, et al. Serum IL-6 level and the development of disability in older patients. J Am Geriatr Soc. 1999;106:506–12.Google Scholar
  38. 38.
    Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder C, Ettinger Jr WH, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506–12.PubMedGoogle Scholar
  39. 39.
    Cossarizza A, Ortolani C, Monti D, Franceschi C. Cytometric analysis of immuno-senescence. Cytometry. 1997;27:297–313.PubMedGoogle Scholar
  40. 40.
    Fagnoni FF, Vescovini RR, Passeri GG, Bologna G, Pedrazzoni M, Lavagetto G, et al. Shortage of circulating of naive CD8(+) T cells provide new insights on immunodeficiency in aging. Blood. 2000;95:2860–8.PubMedGoogle Scholar
  41. 41.
    Breitbart E, Wang X, Leka LS, Dallal GE, Meydani SN, Stollar BD. Altered memory B cell homeostasis in human aging. J Gerontol A Biol Sci Med Sci. 2002;57:B304–11.PubMedGoogle Scholar
  42. 42.
    Pawelec G, Effros RB, Caruso C, Ramarque E, Barnett Y, Solana R. T cells and aging. Front Biosci. 1999;4:D216–69.PubMedGoogle Scholar
  43. 43.
    Linton PJ, Haynes L, Tsui L, Zhang X, Swain S. From naive to effector-alterations with aging. Immunol Rev. 1997;160:9–18.PubMedGoogle Scholar
  44. 44.
    Quyang Q, Wagner WM, Zheng W, Wikby A, Remarque EJ, Pawelec G. Dysfunctional CMV-specific CD8+ cells accumulate in the elderly. Exp Gerontol. 2004;39:607–13.Google Scholar
  45. 45.
    Ferguson FG, Wikby A, Maxson P, Olsson J, Johansson B. Immune parameters in longitudinal study of a very old population of Swedish people: a comparison between survivors and non-survivors. J Gerontol A Biol Sci Med Sci. 1995;50:B378–82.PubMedGoogle Scholar
  46. 46.
    Wikby A, Maxson P, Olsson J, Johansson B, Fergusson FG. Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation responses and non survival in the very old: the Swedish longitudinal OCTO-immune study. Mech Ageing Dev. 1998;102:187–98.PubMedGoogle Scholar
  47. 47.
    Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Fergusson FG. Age related changes in peripheral blood T-lymphocytes subpopulations and cytomegalo-virus infections in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev. 2000;121:187–201.PubMedGoogle Scholar
  48. 48.
    Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies affected by interferon-γ. J Exp Med. 2002;196:129–34.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Imai K, Matsuyama S, Miyaki S, Suga K, Nagachi K. Natural cytotoxic activity of peripheral blood lymphocytes and cancer incidence; an 11 year follow up study of a general population. Lancet. 2000;356:1795–9.PubMedGoogle Scholar
  50. 50.
    Takeuchi H, Maehara Y, Tokunaga Y, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multi-variate analysis. Am J Gastroenterol. 2001;96:574–8.PubMedGoogle Scholar
  51. 51.
    Bonafe M, Valensin S, Gianni W, Marigliano V, Franceschi C. The unexpected contribution of immunosenescence to the levelling off of cancer incidence and mortality in the oldest old. Crit Rev Oncol Hematol. 2001;39:227–33.PubMedGoogle Scholar
  52. 52.
    Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey D, Trapani J. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000;192:755–60.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Jewett A, Tseng HC, Arasteh A, Saddat S, Christensen RE, Cacalano RA. Natural killer cells preferentially target cancer stem cells: role of monocytes in protection against NK cell mediated lysis of cancer stem cells. Curr Drug Deliv. 2011;9(1):5–16.Google Scholar
  54. 54.
    Oh SJ, Ryu CK, Baek SY, Lee H. Cellular mechanism of newly synthesized indoleamine derivative-induced immunological death of tumor cell. Immune Netw. 2011;11(6):383–9.PubMedCentralPubMedGoogle Scholar
  55. 55.
    Pandoffi F, Cianci R, Pagliari D, Casciano F, Bagala C, Astone A, et al. The immune response to tumors as a tool toward immunotherapy. Clin Dev Immunol. 2011. http://www.hindawi.com/journals/cdi/2011/894704/. Accessed on 15 Apr 2012.
  56. 56.
    Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, Kang CW, et al. Tumor-derived chemokine CCL-5 enhances TGF-β-mediated killing of CD8+ T cells in colon cancer by T-regulatory cells. Cancer Res. 2012;72(5):1092–102.PubMedGoogle Scholar
  57. 57.
    Butcher S, Chahal H, Lord JM. Ageing and the neutrophil: no appetite for killing? Immunology. 2000;100:411–6.PubMedGoogle Scholar
  58. 58.
    Rajagopalan S, Yoshikawa TT. Tuberculosis in the elderly. Z Gerontol Geriatr. 2000;33:374–80.PubMedGoogle Scholar
  59. 59.
    Wick G, Grubeck-Loebenstein B. Primary and secondary alterations of immune reactivity in the elderly: impact of dietary factors and disease. Immunol Res. 1997;160:171–84.Google Scholar
  60. 60.
    Weiskopf D, Weinberger D, Grubeck-Lobenstein B. The aging of the immune system. Transpl Int. 2009;22(11):1041–50.PubMedGoogle Scholar
  61. 61.
    Ponnappan S, Ponnappan U. Aging and immune function: molecular mechanisms to inventions. Antioxid Redox Signal. 2011;14(8):1551–85.PubMedGoogle Scholar
  62. 62.
    Basile G, Paffumi I, D’Angelo AG, Figliomreni P, Cucinotta MD, Pace E, et al. Health centenarians show high levels of interleukin-22. Arch Gerontol Geriatr. 2011;54(3):459–61.PubMedGoogle Scholar
  63. 63.
    Perera RY, Lichy JH, Waldman TR, Perera LP. The role of interleukin-15 in inflammation and immune responses. Microbes Infect. 2012;14(3):247–61.PubMedCentralPubMedGoogle Scholar
  64. 64.
    Ghiringhelli F, Rebe C, Hichami A, Delmas D. Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents. Anticancer Agents Med Chem. 2012;12(8):852–73.PubMedGoogle Scholar
  65. 65.
    Khanna KW, Markan RB. A perspective on cellular immunity in the elderly. Clin Infect Dis. 1999;28:710–3.PubMedGoogle Scholar
  66. 66.
    Chandra RK. Effect of vitamin and trace element supplementation on immune responses and infections in the elderly subjects. Lancet. 1992;340:1124–7.PubMedGoogle Scholar
  67. 67.
    Maestroni GJ, Conti A, Pierpaoli W. Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol. 1986;13:19–30.PubMedGoogle Scholar
  68. 68.
    Maestroni GJ, Conti A, Pierpaoli W. Role of the pineal gland in immunity: II. Melatonin enhances the antibody response via an opiatergic mechanism. Clin Exp Immunol. 1987;8:384–91.Google Scholar
  69. 69.
    Maestroni GJ, Conti A, Pierpaoli W. The pineal gland and the circadian, opiatergic, immunoregulatory role of melatonin. Ann N Y Acad Sci. 1987;496:67–77.PubMedGoogle Scholar
  70. 70.
    Moore CB, Siopes TD. Effect of melatonin supplementation on the ontogeny of immunity in the large White turkey poult. Poult Sci. 2002;81:1898–903.PubMedGoogle Scholar
  71. 71.
    Gonzalez-Haba MG, Garcia-Maurino S, Calvo JR, Goberna R, Guerrero JM. High affinity binding of melatonin by human circulating T lymphocytes (CD4+). FASEB J. 1995;9:1331–5.PubMedGoogle Scholar
  72. 72.
    Garcia-Perganeda A, Pozo D, Guerrero JM, Calvo JR. Signal transduction for melatonin in human lymphocytes: involvement of a pertussis toxin sensitive G-protein. J Immunol. 1997;159:3774–81.PubMedGoogle Scholar
  73. 73.
    Carrillo-Vico A, Garcia-Maurino S, Calvo JR, Guerrero JM. Melatonin counteracts the inhibitory effect of PGE-2 on interleukin-2 production in human lymphocytes via its mt1 membrane receptor. FASEB J. 2003;17:755–7.PubMedGoogle Scholar
  74. 74.
    Maestroni GJ, Conti A, Lissoni P. Colony stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin-4. Cancer Res. 1994;54:4740–3.PubMedGoogle Scholar
  75. 75.
    Maestroni GJ, Covacci V, Conti A. Hematopoietic rescue via T cell dependent endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor bearing mice. Cancer Res. 1994;54:2429–32.PubMedGoogle Scholar
  76. 76.
    Kaur C, Ling EA. Effects of melatonin on macrophages/microglia in post natal rat brain. J Pineal Res. 1999;26:158–68.PubMedGoogle Scholar
  77. 77.
    Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs. 2001;10:467–76.PubMedGoogle Scholar
  78. 78.
    Angeli A, Gatti G, Sartori ML, Ponte D, Carignola R. Effect of exogenous melatonin on human natural killer cell (NK) cell activity. In: Gupta D, Attansio A, Reiter RJ, editors. An approach to the immunomodulatory role of the pineal gland. Tubingen: Brain Research Promotion; 1988. p. 145–56.Google Scholar
  79. 79.
    Currier NL, Sun LZ, Miller SC. Exogenous melatonin: quantitative enhancement in vivo of cells mediating non-specific immunity. J Neuroimmunol. 2000;104:101–8.PubMedGoogle Scholar
  80. 80.
    Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol. 2007;211:144–56.PubMedCentralPubMedGoogle Scholar
  81. 81.
    Csaba G, Barath P. Morphological changes of thymus and thyroid gland after post-natal extirpation of pineal body. Endocrinol Exp. 1975;9:59–67.PubMedGoogle Scholar
  82. 82.
    Hoijman E, Rocha-Viegas L, Keller-Sarmiento MI, Rosenstein RE, Pecci A. Involvement of Bax protein in the prevention of glucocorticoid-induced thymocytes apoptosis by melatonin. Endocrinology. 2004;145(1):418–25.PubMedGoogle Scholar
  83. 83.
    Tian TM, Li PP, Jiang XF, Zhang GY, Dai YR. Rejuvenation of degenerative thymus by oral melatonin administration and the antagonistic action of melatonin against hydroxyl radical induced apoptosis of cultured thymocytes in mice. J Pineal Res. 2001;31:214–21.PubMedGoogle Scholar
  84. 84.
    Raghavendra V, Singh V, Kulkarni SK, Agrewala JN. Melatonin enhances Th2 cell mediated: lack of sensitivity to reversal by naltrexone or benzodiazepine receptor antagonists. Mol Cell Biochem. 2001;221:57–62.PubMedGoogle Scholar
  85. 85.
    Calcagni E, Elenkov I. Stress system activity, innate, and T helper cytokines, and susceptibility to immune related diseases. Ann N Y Acad Sci. 2006;1069:62–76.PubMedGoogle Scholar
  86. 86.
    Chaouat G. The Th1/Th2 paradigm still important in pregnancy? Semin Immunopathol. 2007;29:95–113.PubMedGoogle Scholar
  87. 87.
    Srinivasan V, Spence DW, Trakht I, Pandi-Perumal SR, Cardinali DP, Maestroni GJ. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation. 2008;15:93–101.PubMedGoogle Scholar
  88. 88.
    Liu F, Ng TB, Fung MC. Pineal indoles stimulate the gene expression of immuno-modulating cytokines. J Neural Transm. 2001;108:397–405.PubMedGoogle Scholar
  89. 89.
    Nunnari G, Nigro L, Palermo F, Leto D, Pomerantz RJ, Cacopardo B. Reduction of serum melatonin levels in HIV-1 infected individuals parallel disease progression: correlation with serum interleukin-12 levels. Infection. 2003;31:379–82.PubMedGoogle Scholar
  90. 90.
    Kidd P. Th1/Th2 balance: the hypothesis, its limitations and implications for health and disease. Altern Med Rev. 2003;8:223–46.PubMedGoogle Scholar
  91. 91.
    Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C. Glutathione levels in antigen-presenting cells modulates Th1 versus Th2 receptor patterns. Proc Natl Acad Sci U S A. 1998;95:3071–6.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Murata Y, Shimamura T, Hamuro J. The polarization of Th1/Th2 balance is dependent on the intracellular thiol redox status of macrophages due to its distinctive cytokine production. Int Immunol. 2002;14:201–12.PubMedGoogle Scholar
  93. 93.
    Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafil-el-Idrissi M, Sanchez-Margalet V, Goberna R, et al. Melatonin enhances IL-2, IL-6, and IFNγ production by human circulating CD4+ cells: a possible nuclear receptor mediated mechanism involving T helper type1 lymphocytes, and monocytes. J Immunol. 1997;159:574–81.PubMedGoogle Scholar
  94. 94.
    Lardone PJ, Guerrero JM, Fernandez-Santos JM, Martin-Laeve I, Carrillo-Vico A. Melatonin synthesized by T lymphocytes as a ligand of the retinoic acid related orphan receptor. J Pineal Res. 2011;51(4):454–62.PubMedGoogle Scholar
  95. 95.
    Garcia-Maurino S, Pozo D, Carrillo-Vico A, Calvo JR, Guerrero JM. Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sci. 1999;65:2143–50.PubMedGoogle Scholar
  96. 96.
    Morrey KM, McLachlan JA, Serkin CD, Bakouche O. Activation of human monocytes by the pineal hormone melatonin. J Immunol. 1994;153:2671–80.PubMedGoogle Scholar
  97. 97.
    Bilbo SD, Nelson RJ. Melatonin regulates energy balance and attenuates fever in Siberian hamsters. Endocrinology. 2002;143:2527–33.PubMedGoogle Scholar
  98. 98.
    Wen JC, Dhabbar FS, Prendergast BJ. Pineal dependent and independent effect of photoperiod on immune function in Siberian Hamsters (Phodopus sungorus). Horm Behav. 2007;51:31–9.PubMedCentralPubMedGoogle Scholar
  99. 99.
    Silva SO, Rodriguez MR, Carvalho SR, Catalani LH, Campa A, Ximenes VF. Oxidation of melatonin and its catabolites, N-acetyl-N-formyl 5 methoxy-kynuramine by activated leukocytes. J Pineal Res. 2004;37:171–5.PubMedGoogle Scholar
  100. 100.
    Silva SO, Rodriguez MR, Xieminas VF, Bueno-da-silva AE, Amarantes-Mendes GP, Campa A. Neutrophils as specific target for melatonin and kynuramine: effects on cytokine release. J Neuroimmunol. 2004;156:146–52.PubMedGoogle Scholar
  101. 101.
    Adams DH, Llyod AR. Chemokines: leukocyte recruitment and activation cytokines. Lancet. 1997;349:490–5.PubMedGoogle Scholar
  102. 102.
    Knutson KL, Disis ML. Tumor-antigen specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005;54:721–8.PubMedGoogle Scholar
  103. 103.
    Martin-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andres O, Gonsalez P, Gonsalez-Gallego J. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res. 2008;45:532–40.PubMedGoogle Scholar
  104. 104.
    Ozdemir F, Deniz O, Kayner K, Arslan M, Kavgaci H, Yildiz B, et al. The effect of melatonin on human hepatoma (Hep G2) cell line. Bratisl Lek Listy. 2009;110:276–9.PubMedGoogle Scholar
  105. 105.
    Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP, Cardinali DP. Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov. 2011;5:109–23.PubMedGoogle Scholar
  106. 106.
    Lissoni P, Brivio F, Ardizzoia A, Tancini G, Barni S. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Tumori. 1993;79:401–4.PubMedGoogle Scholar
  107. 107.
    Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Meregalli S, Fossati V, et al. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colon-cancer patients progressing under 5-fluorouracil and folates. Oncology. 1995;52:243–5.PubMedGoogle Scholar
  108. 108.
    Muc-Wierzgon M, Nowakowska-Zajdel E, Zubelewicz B, Wierzgon J, Kokot T, Klala K, et al. Circadian fluctuations of melatonin, tumor necrosis factor α and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer. J Exp Clin Cancer Res. 2003;22:171–8.PubMedGoogle Scholar
  109. 109.
    Jung B, Ahmad N. Melatonin in cancer management: progress and promise. Cancer Res. 2006;66:9789–93.PubMedGoogle Scholar

Copyright information

© Springer India 2014

Authors and Affiliations

  • Mahaneem Mohamed
    • 1
    Email author
  • Venkataramanujam Srinivasan
    • 2
    • 3
    • 4
  • Georges Maestroni
    • 5
  • Ruth E. Rosenstein
    • 6
  • Sukru Oter
    • 7
  1. 1.Department of PhysiologySchool of Medical Sciences, Universiti Sains MalaysiaKubang KerianMalaysia
  2. 2.Sri Sathya Sai Medical Educational and Research Foundation, An International Medical Sciences Research Study CenterCoimbatoreIndia
  3. 3.National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and TreatmentHospital “G. Mazzini”TeramoItaly
  4. 4.Department of Neuroscience and ImagingUniversity “G.D’ Annunzio”ChietiItaly
  5. 5.Department of PharmacologyUniversity of Insubria, Medical SchoolVareseItaly
  6. 6.Department of Human BiochemistrySchool of Medicine/CEFyBO, University of Buenos Aires/CONICETBuenos AiresArgentina
  7. 7.Department of PhysiologyGulhane Military Medical AcademyAnkaraTurkey

Personalised recommendations